Cordycepin Targets HRD1 to Promote Cancer Cell PD-L1 Ubiquitin–Proteasome Degradation and Increase Antitumor Immunity

Abstract

Immune checkpoint blockade has become an effective strategy for inhibiting tumor growth, especially immune checkpoint inhibitors that target the programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway, which have shown significant effects in tumor immunotherapy. In this study, we found that naturally sourced Cordyceps militaris extract can effectively downregulate the protein expression level of PD-L1 in human colorectal cancer cell lines. Further systematic isolation, purification, and analysis of its active components revealed that cordycepin (COR) is the key active molecule mediating PD-L1 degradation. Mechanistically, COR specifically and selectively targets the ubiquitin E3 ligase HMG-CoA reductase degradation protein 1, thus promoting the degradation of PD-L1 protein through the ubiquitin–proteasome pathway. This process significantly enhances the cytotoxic killing effect of effector T lymphocytes against colorectal cancer cells, ultimately achieving robust antitumor effects. Furthermore, this study also revealed that COR exhibits potential synergistic therapeutic effects when combined with anti-CTLA4 antibodies in preclinical tumor treatment. In summary, COR, as the primary bioactive component of Cordycepsmilitaris, demonstrates considerable potential to act as a small-molecule immune checkpoint modulator and inhibitor, thereby providing a novel therapeutic strategy for the immunotherapy of colorectal cancer.

Keywords

Cordyceps militaris extract (CME) / cordycepin (COR) / colorectal cancer (CRC) / HMG-CoA reductase degradation protein 1 (HRD1) / programmed death-ligand 1 (PD-L1)

References

[1] S. M. Schwartz, “Epidemiology of Cancer,” Clinical Chemistry 70, no. 1 (2024): 140-149.

[2] A. E. Shin, F. G. Giancotti, and A. K. Rustgi, “Metastatic Colorectal Cancer: Mechanisms and Emerging Therapeutics,” Trends in Pharmacological Sciences 44, no. 4 (2023): 222-236.

[3] W. Zhao, L. Jin, P. Chen, D. Li, W. Gao, and G. Dong, “Colorectal Cancer Immunotherapy-Recent Progress and Future Directions,” Cancer Letters 545 (2022): 215816.

[4] A. Chow, K. Perica, C. A. Klebanoff, and J. D. Wolchok, “Clinical Implications of T Cell Exhaustion for Cancer Immunotherapy,” Nature Reviews Clinical Oncology 19, no. 12 (2022): 775-790.

[5] W. Li, F. Wu, S. Zhao, P. Shi, S. Wang, and D. Cui, “Correlation Between PD-1/PD-L1 Expression and Polarization in Tumor-associated Macrophages: A Key Player in Tumor Immunotherapy,” Cytokine & Growth Factor Reviews 67 (2022): 49-57.

[6] M. E. Keir, M. J. Butte, G. J. Freeman, and A. H. Sharpe, “PD-1 and Its Ligands in Tolerance and Immunity,” Annual Review of Immunology 26 (2008): 677-704.

[7] M. Yi, M. Niu, L. Xu, S. Luo, and K. Wu, “Regulation of PD-L1 Expression in the Tumor Microenvironment,” Journal of Hematology & Oncology 14, no. 1 (2021): 10.

[8] K. Liu, Q. Sun, Q. Liu, H. Li, W. Zhang, and C. Sun, “Focus on Immune Checkpoint PD-1/PD-L1 Pathway: New Advances of Polyphenol Phytochemicals in Tumor Immunotherapy,” Biomedicine & Pharmacotherapy 154 (2022): 113618.

[9] J. Chen, Z. Lin, L. Liu, et al., “GOLM1 exacerbates CD8(+) T Cell Suppression in Hepatocellular Carcinoma by Promoting Exosomal PD-L1 Transport Into Tumor-associated Macrophages,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 397.

[10] L. Ding, X. Chen, W. Zhang, et al., “Canagliflozin Primes Antitumor Immunity by Triggering PD-L1 Degradation in Endocytic Recycling,” Journal of Clinical Investigation 133, no. 1 (2023): e154754.

[11] Q. Wang, J. Wang, D. Yu, et al., “Benzosceptrin C Induces Lysosomal Degradation of PD-L1 and Promotes Antitumor Immunity by Targeting DHHC3,” Cell Reports Medicine 5, no. 2 (2024): 101357.

[12] L. Liu, Y. Jing, A. Guo, et al., “Biosynthesis of Platinum Nanoparticles With Cordyceps Flower Extract: Characterization, Antioxidant Activity and Antibacterial Activity,” Nanomaterials (Basel) 12, no. 11 (2022): 1904.

[13] K. V. Krishna, R. S. Ulhas, and A. Malaviya, “Bioactive Compounds From Cordyceps and Their Therapeutic Potential,” Critical Reviews in Biotechnology 44, no. 5 (2024): 753-773.

[14] G. Zhulai and E. Oleinik, “Targeting Regulatory T Cells in Anti-PD-1/PD-L1 Cancer Immunotherapy,” Scandinavian Journal of Immunology 95, no. 3 (2022): e13129.

[15] L. Shen, Z. Su, K. Yang, et al., “Structure of the Translating Neurospora Ribosome Arrested by Cycloheximide,” PNAS 118, no. 48 (2021): e2111862118.

[16] Z. Miao, J. Li, Y. Wang, et al., “Hsa_circ_0136666 stimulates Gastric Cancer Progression and Tumor Immune Escape by Regulating the miR-375/PRKDC Axis and PD-L1 Phosphorylation,” Molecular Cancer 22, no. 1 (2023): 205.

[17] C. Shi, Y. Wang, M. Wu, et al., “Promoting Anti-tumor Immunity by Targeting TMUB1 to Modulate PD-L1 Polyubiquitination and Glycosylation,” Nature Communications 13, no. 1 (2022): 6951.

[18] H. Yao, J. Lan, C. Li, et al., “Inhibiting PD-L1 Palmitoylation Enhances T-cell Immune Responses Against Tumours,” Nature Biomedical Engineering 3, no. 4 (2019): 306-317.

[19] Y. Gao, N. T. Nihira, X. Bu, et al., “Acetylation-dependent Regulation of PD-L1 Nuclear Translocation Dictates the Efficacy of anti-PD-1 Immunotherapy,” Nature Cell Biology 22, no. 9 (2020): 1064-1075.

[20] P. Ding, Z. Ma, Y. Fan, et al., “Emerging Role of Ubiquitination/Deubiquitination Modification of PD-1/PD-L1 in Cancer Immunotherapy,” Genes & Diseases 10, no. 3 (2023): 848-863.

[21] Z. Li, X. Yu, Z. Yuan, L. Li, and P. Yin, “New Horizons in the Mechanisms and Therapeutic Strategies for PD-L1 Protein Degradation in Cancer,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1879, no. 5 (2024): 189152.

[22] S. Han, R. Wang, Y. Zhang, et al., “The Role of Ubiquitination and Deubiquitination in Tumor Invasion and Metastasis,” International Journal of Biological Sciences 18, no. 6 (2022): 2292-2303.

[23] S. C. Chang, B. X. Zhang, and J. L. Ding, “E2-E3 ubiquitin Enzyme Pairing—partnership in Provoking or Mitigating Cancers,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877, no. 2 (2022): 188679.

[24] J. Ren, P. Yu, S. Liu, et al., “Deubiquitylating Enzymes in Cancer and Immunity,” Advanced Science (Weinheim) 10, no. 36 (2023): e2303807.

[25] J. Xia, M. Xu, H. Hu, et al., “5,7,4'-Trimethoxyflavone Triggers Cancer Cell PD-L1 Ubiquitin-proteasome Degradation and Facilitates Antitumor Immunity by Targeting HRD1,” MedComm 5, no. 7 (2024): e611.

[26] Y. Liao, Y. Liu, C. Yu, et al., “HSP90β Impedes STUB1-Induced Ubiquitination of YTHDF2 to Drive Sorafenib Resistance in Hepatocellular Carcinoma,” Advanced Science (Weinheim) 10, no. 27 (2023): e2302025.

[27] X. Liu, F. Xu, L. Ren, et al., “MARCH8 inhibits influenza A Virus Infection by Targeting Viral M2 Protein for Ubiquitination-dependent Degradation in Lysosomes,” Nature Communications 12, no. 1 (2021): 4427.

[28] H. Zhang, X. Jin, and H. Huang, “Deregulation of SPOP in Cancer,” Cancer Research 83, no. 4 (2023): 489-499.

[29] K. Wang, P. Coutifaris, D. Brocks, et al., “Combination anti-PD-1 and Anti-CTLA-4 Therapy Generates Waves of Clonal Responses That Include Progenitor-exhausted CD8(+) T Cells,” Cancer Cell 42, no. 9 (2024): 1582-1597. e10.

[30] M. Maio, P. A. Ascierto, L. Manzyuk, et al., “Pembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: Updated Analysis From the Phase II KEYNOTE-158 Study,” Annals of Oncology 33, no. 9 (2022): 929-938.

[31] S. J. Wang, S. K. Dougan, and M. Dougan, “Immune Mechanisms of Toxicity From Checkpoint Inhibitors,” Trends in Cancer 9, no. 7 (2023): 543-553.

[32] F. G. Dall'Olio, A. Marabelle, C. Caramella, et al., “Tumour Burden and Efficacy of Immune-checkpoint Inhibitors,” Nature Reviews Clinical Oncology 19, no. 2 (2022): 75-90.

[33] M. Tang and S. Kalim, “Avenues for Post-translational Protein Modification Prevention and Therapy,” Molecular Aspects of Medicine 86 (2022): 101083.

[34] C. Feng, L. Zhang, X. Chang, D. Qin, and T. Zhang, “Regulation of Post-translational Modification of PD-L1 and Advances in Tumor Immunotherapy,” Frontiers in Immunology 14 (2023): 1230135.

[35] J. H. Cha, L. C. Chan, C. W. Li, J. L. Hsu, and M. C. Hung, “Mechanisms Controlling PD-L1 Expression in Cancer,” Molecular Cell 76, no. 3 (2019): 359-370.

[36] C. W. Li, S. O. Lim, W. Xia, et al., “Glycosylation and Stabilization of Programmed Death Ligand-1 Suppresses T-cell Activity,” Nature Communications 7 (2016): 12632.

[37] C. W. Li, S. O. Lim, E. M. Chung, et al., “Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1,” Cancer Cell 33, no. 2 (2018): 187-201. e10.

[38] S. Wu, W. Fang, L. Chen, et al., “Cordycepin Remodels the Tumor Microenvironment of Colorectal Cancer by Down-regulating the Expression of PD-L1,” Journal of Cancer Research and Clinical Oncology 149, no. 19 (2023): 17567-17579.

[39] J. Chen, R. S. Liang, B. B. Zhuang, et al., “Cordycepin Inhibits Glioma Growth by Downregulating PD-L1 Expression via the NOD-Like Receptor/NFKB1/STAT1 Axis,” Chemico-Biological Interactions 400 (2024): 111178.

[40] X. Gao, N. Xu, Z. Li, et al., “Safety and Antitumour Activity of cadonilimab, an Anti-PD-1/CTLA-4 Bispecific Antibody, for Patients With Advanced Solid Tumours (COMPASSION-03): A Multicentre, Open-label, Phase 1b/2 Trial,” The Lancet Oncology 24, no. 10 (2023): 1134-1146.

[41] R. Váraljai, L. Zimmer, Y. Al-Matary, et al., “Interleukin 17 Signaling Supports Clinical Benefit of Dual CTLA-4 and PD-1 Checkpoint Inhibition in Melanoma,” Nat Cancer 4, no. 9 (2023): 1292-1308.

[42] I. Pires da Silva, I. Li, and S. Ugurel, “Anti-PD-1 Alone or in Combination With anti-CTLA-4 for Advanced Melanoma Patients With Liver Metastases,” European Journal of Cancer 205 (2024): 114101.

[43] B. Virassamy, F. Caramia, P. Savas, et al., “Intratumoral CD8(+) T Cells With a Tissue-resident Memory Phenotype Mediate Local Immunity and Immune Checkpoint Responses in Breast Cancer,” Cancer Cell 41, no. 3 (2023): 585-601. e8.

[44] X. Zhou, D. Fang, H. Liu, et al., “PMN-MDSCs Accumulation Induced by CXCL1 Promotes CD8(+) T Cells Exhaustion in Gastric Cancer,” Cancer Letters 532 (2022): 215598.

[45] H. Sui, S. Dongye, X. Liu, et al., “Immunotherapy of Targeting MDSCs in Tumor Microenvironment,” Frontiers in Immunology 13 (2022): 990463.

[46] H. Liu, Z. Wang, Y. Zhou, and Y. Yang, “MDSCs in Breast Cancer: An Important Enabler of Tumor Progression and an Emerging Therapeutic Target,” Frontiers in Immunology 14 (2023): 1199273.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.